Uncategorized

Advisory boards are one of the most vital strategic tools available to Medical Affairs teams. When assembled effectively, they provide unvarnished clinical insights, identify unaddressed patient needs, and shape early-to-late-stage drug development strategies. However, the traditional process of identifying advisors and preparing agendas is increasingly out of step with today’s fast-moving medical landscape. Medical Affairs teams are under immense pressure to move away from legacy networks and build dynamic, data-driven advisory boards that reflect true clinical consensus.

Most commercial teams in life sciences companies already have access to KOL data. What they lack is a reliable way to turn that data into an engagement strategy that works consistently across therapy areas, geographies, and the full range of experts who actually influence treatment decisions. The problem is that commercial KOL engagement doesn’t scale the way most strategies are built. It works well for the most visible national experts, then breaks down as teams move deeper into the landscape. Community opinion leaders, emerging KOLs, and local clinical influencers tend to fall outside the reach of traditional approaches not because intelligence doesn’t exist, but because most platforms aren’t built to connect it in a way commercial teams can act on.

Most field teams in life sciences companies already have access to KOL profiles. The real challenge is ensuring that this information stays current, relevant, and ready to use before every interaction. A KOL’s research interests, publications, collaborations, and perspectives can change quickly, and relying on outdated information often results in conversations that feel routine instead of meaningful.

Most life sciences companies have access to static KOL lists. The challenge is that healthcare influence doesn’t stay definite. New experts emerge, conversations shift, and local physician communities often respond to different voices than the ones appearing on traditional KOL rankings.
A list that was relevant six months ago may not reflect who is driving conversations today.

Most life sciences companies have no shortage of KOL data. What they often lack is a reliable way to identify which experts are becoming more influential, which conversations are gaining momentum, and where engagement efforts should be focused. This is where Neolytica’s TiExpert helps teams move beyond static KOL lists and towards a more dynamic and real time understanding of influence.

Healthcare trends often begin with small shifts in KOL conversations. New evidence gets discussed, clinical experiences are exchanged, and different perspectives start circulating across professional networks. Over time, these discussions begin influencing how therapies are perceived and applied in clinical settings.

By the time the trend becomes visible in broader market data, the conversation behind it has often been evolving for months.

Understanding that process is important for Medical Affairs, Commercial, and field teams trying to stay aligned with how the landscape is moving.

Most shifts in healthcare start quietly. Before a therapy gains momentum, before prescribing behavior changes, and before a trend becomes obvious, something usually changes in expert conversations first.
The challenge is that these signals do not look dramatic in the beginning. They appear gradually and across different sources at the same time. A single comment or discussion may not mean much on its own, but repeated patterns often indicate that the landscape is starting to evolve.

Most teams have access to KEE insights. They know who the key experts are, what they’re publishing, where they’re speaking, and how active they are. In many cases, they also have dashboards that track engagement and activity over time.

Scientific information doesn’t move in a straight line. A new study, conference presentation, or clinical observation enters a network of experts, where it is discussed, interpreted, and shared across multiple touchpoints.

Most teams recognize a trend only after it shows up in data. By then, it’s already in motion.
In healthcare, adoption doesn’t start with prescriptions or performance metrics. It starts earlier, when experts begin to question, discuss, or reinterpret something.

Product adoption in healthcare usually unfolds gradually. Before prescribing patterns begin to shift, conversations among experts start to evolve. New evidence is discussed at conferences, mechanisms are debated in publications, and clinicians share their perspectives within their professional networks.